Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
Trial ID or NCT#
Status
Purpose
Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
Official Title
Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
Eligibility Criteria
- - PSC Diagnosis: Liver biopsy and/or imaging (MRCP, ERCP, CT, or US - Colonoscopy within 1 year or starting of study - 2 groups: 1. IBD (Inflammatory bowel disease) and PSC: details of extent and type of IBD 2. No IBD and PSC, but positive p-ANCA or ASCA serologies indicating possible IBD.
- - Allergy to Vancomycin - PSC not associated with IBD or NO positive IBD antibodies (p-ANCA [anti- neutrophil cytoplasmic antibody] or ASCA [anti-Saccharomyces cerevisiae antibody]) - Cholangiocarcinoma - On oral or topical (enemas or suppositories) corticosteroids,topical mesalamine, or biologics (infliximab, adalimumab, certolizumab).
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Ken Cox, MD
650-721-2250
View on ClinicalTrials.gov